se gb

Press Releases

Change of Number of Shares and Votes in Karolinska Development

STOCKHOLM - April 28, 2017. The number of series B shares in Karolinska Development AB (Nasdaq Stockholm: KDEV) has increased by 10,871,698 shares via the allotment in the set off issue resolved by the board (conditional of the approval by the General Meeting) and approved by the Extraordinary General Meeting on March 8, 2017.

Today, the last trading day of the month, there are 64,336,696 shares, representing a total of 77,864,578 votes outstanding in the Company, distributed among 1,503,098 shares of series A (with 15,030,980 votes) and 62,833,598 shares of series B (with 62,833,598 votes).

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09   , e-mail: jim.van.heusden@karolinskadevelopment.com 

Ulf Richenberg, General Counsel, Karolinska Development AB
Phone: +46 70 29 860 25, e-mail: ulf.richenberg@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571   ; e-mail: KDev@citigatedr.co.uk

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of Jim Van heusden, at 08.00 CET on April 28, 2017.

PDF    PR Number of shares change